Insulin Detemir

證據等級: L5

預測適應症: 10 個

Insulin Detemir: From Diabetes Mellitus (Original Indication Not Recorded) to Type 1 Diabetes Mellitus — Data Gap Flagged, Not a Genuine Repurposing Signal

One-Sentence Summary

Insulin detemir (DrugBank DB01307, marketed globally as Levemir) is a long-acting basal insulin analogue already used to treat type 1 and type 2 diabetes. The TxGNN model's top prediction — Type 1 Diabetes Mellitus — is not a new indication at all; it is the drug's own well-established, already-approved use. This candidate exists only because the evidence pack's original_indications field is empty and market_status incorrectly shows "not marketed," which are data gaps in the source registry rather than a genuine repurposing discovery. 34 clinical trials and 20 publications support insulin detemir's efficacy in type 1 diabetes — but as confirmation of known use, not as new-indication evidence.

Quick Overview

Item	Content
Original Indication	Not recorded in this evidence pack (registry data gap). Publicly, insulin detemir (Levemir) is indicated for type 1 and type 2 diabetes mellitus.
Predicted "New" Indication	Type 1 diabetes mellitus — identical to the drug's real-world established use
TxGNN Prediction Score	99.77% (rank 2954)
Evidence Level	L1 (≥2 completed Phase 3 RCTs) — reflects existing-use evidence, not novel-indication evidence
Norway Market Status	未上市 (Not marketed) — flagged as likely inaccurate given Levemir's known global marketing history
Number of Authorizations	0
Recommended Decision	Hold (pending data verification)

Why is This Prediction Reasonable?

Mechanistically, insulin detemir is straightforward: it is a soluble, long-acting human insulin analogue acylated with a 14-carbon fatty acid, which reversibly binds albumin to provide slow, prolonged absorption. This directly replaces the endogenous insulin deficiency that defines type 1 diabetes mellitus (T1DM), which is why it makes pharmacological sense — because it is already the standard basal insulin therapy for T1DM, not because TxGNN uncovered a novel mechanistic link.

This is the central issue with this candidate: the "original indication → new indication" relationship the report template expects does not exist here. The evidence pack itself flags this in repurposing_rationale: "此為藥物之原始核准適應症（非老藥新用候選）" — this is the drug's original approved indication, not a repurposing candidate. The high TxGNN score and abundant clinical/literature evidence reflect the strength of insulin detemir's established use in T1DM, not the discovery of a new therapeutic avenue.

Two data gaps in the source pack likely caused this false-positive framing: (1) original_indications is empty, so the pipeline had no baseline indication to compare against, and (2) market_status shows "not marketed" with zero licenses, which is inconsistent with Levemir's known international market presence. Both should be corrected at the source (DrugBank/national regulatory registry) before this drug is evaluated further in any repurposing workflow.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00474045	Phase 3	Completed	470	Insulin detemir vs NPH insulin (both + aspart) in pregnant women with T1DM; glycemic control and safety comparison
NCT00312156	Phase 3	Completed	347	Detemir vs NPH insulin in children/adolescents with T1DM, once or twice daily + mealtime aspart
NCT03220425	Phase 3	Completed	752	Efficacy/safety of detemir (2400 nmol/mL formulation) vs NPH in T1DM basal-bolus regimen
NCT01486940	Phase 3	Completed	598	Detemir + aspart vs NPH + human soluble insulin in T1DM basal-bolus regimen
NCT00117780	Phase 4	Completed	520	Once-daily vs twice-daily detemir + aspart in T1DM: HbA1c, hypoglycemia, weight
NCT00595374	Phase 3	Completed	114	Detemir + aspart vs NPH + aspart in adults with T1DM
NCT01835431	Phase 3	Completed	362	Degludec/aspart vs detemir once/twice daily + aspart in children/adolescents with T1DM
NCT00655200	N/A (observational)	Completed	2286	Post-marketing safety/tolerability of Levemir (detemir) in Filipino T1DM/T2DM patients
NCT02518945	Phase 3	Completed	26	Dapagliflozin add-on to liraglutide + insulin (incl. detemir as background) in T1DM
NCT00591227	Phase 4	Completed	176	ED-initiated basal-bolus insulin (incl. detemir) for hyperglycemia management

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36623517	2023	RCT	Lancet Diabetes Endocrinol	EXPECT trial: degludec vs detemir (both + aspart) in pregnant women with T1DM, non-inferiority design
29477399	2018	Systematic Review/Network Meta-analysis	Value Health	Comparative efficacy/safety of basal insulin regimens (incl. detemir) in adults with T1DM
33662147	2021	Cochrane Systematic Review	Cochrane Database Syst Rev	Review of (ultra-)long-acting insulin analogues, including detemir, for T1DM
21878861	2011	Systematic Review/Meta-analysis	Pol Arch Med Wewn	Detemir vs NPH insulin in T1DM: glycemic control outcomes
36763996	2022	Systematic Review/Meta-analysis	Clin Ther	Degludec vs other long-acting basal analogues (glargine, detemir) in T1D/T2D
37290466	2023	Review	Lancet Diabetes Endocrinol	Management of T1DM in pregnancy: lifestyle, pharmacological treatment, technology
15516157	2004	Review	Drugs	Insulin detemir: review of use in T1DM and T2DM management
20539842	2010	Review	Vasc Health Risk Manag	Update on T1DM/T2DM treatment, focus on insulin detemir
17326333	2006	Review	Vasc Health Risk Manag	Insulin detemir in the treatment of T1DM and T2DM
15691219	2005	Review	BioDrugs	Spotlight on insulin detemir in T1DM and T2DM

Norway Market Information

No marketing authorization records are present in this evidence pack (total_licenses = 0, market_status = 未上市/Not marketed). This is flagged as a likely data gap rather than fact: insulin detemir (Levemir, Novo Nordisk) has a long-standing global marketing history including in European markets. Before any downstream decision is made on this candidate, the Norwegian Medicines Agency (Legemiddelverket) register should be checked directly to confirm actual market status and authorization numbers.

Safety Considerations

Please refer to the package insert for safety information. (key_warnings, contraindications, and DDI data are all unavailable in this evidence pack — DG001 is flagged as a Blocking data gap that prevents S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale: This is not a genuine repurposing candidate — the "predicted new indication" (T1DM) is insulin detemir's own established, already-approved use. The high TxGNN score and rich evidence base confirm known pharmacology rather than reveal anything new. Proceeding under a "Proceed with Guardrails" label (as the raw scoring engine suggests) would risk misrepresenting a data-pipeline artifact as a discovery. Additionally, DG001 (missing TFDA/regulatory label warnings and contraindications) is a Blocking gap that independently prevents any safety pre-assessment (S1) regardless of indication novelty.

To proceed, the following is needed:

Correct the original_indications field at the source (DrugBank) so insulin detemir is not re-flagged as a "new" T1DM candidate
Verify actual Norway/EU market status and authorization numbers directly against Legemiddelverket, since market_status = 未上市 appears inconsistent with Levemir's known marketing history
Retrieve TFDA/EMA package insert warnings and contraindications (DG001) before any safety-stage evaluation
Retrieve DrugBank MOA record (DG002) to support future mechanistic analyses
For lower-ranked candidates in this batch (autoimmune oophoritis, opsismodysplasia, stiff person syndrome, drug-induced lipodystrophy, etc.), no further action is warranted: these are flagged in the source rationale as comorbidity confounding or reversed-causality artifacts (e.g., lipodystrophy is a known adverse effect of insulin injection, not a treatable indication) rather than credible repurposing signals
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.